Phase I Study of [111In]-FPI-2107 in EGFR Mutation-positive NSCLC

Abroad (travel likely)RecruitingPHASE1

Conditions

EGFR Mutation-positive NSCLC

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

Research Site, Beijing, China
Research Site, Shandong, China
Research Site, Wuhan, China

View source on ClinicalTrials.gov

Similar trials

Other trials that are currently recruiting and may be relevant based on condition, treatment, phase, or location

APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors

Solid Tumors · Advanced Cancer · Renal Cancer

Abroad (travel likely)RecruitingPHASE2

Los Angeles, United States · Tampa, United States

IN10018 Combination Therapy in Advanced EGFR Mutation-positive NSCLC

NSCLC

Abroad (travel likely)RecruitingPHASE1, PHASE2

Shanghai, China

Neoadjuvant Befotertinib Combined Bevacizumab or Platinum-based Double Chemotherapy for Resectable Locally-advanced EGFR Mutation-positive Non-Small Cell Lung Cancer

EGFR · Non-Small Cell Lung Cancer · Locally Advanced Non-Small Cell Lung Cancer

Abroad (travel likely)RecruitingPHASE2

Shanghai, China

A Study With Central Nervous System Metastatic EGFR Mutation Positive Non-small Cell Lung Cancer

NSCLC

Abroad (travel likely)Recruiting

Changsha, China